Haemonetics Past Earnings Performance
Past criteria checks 5/6
Haemonetics has been growing earnings at an average annual rate of 15.2%, while the Medical Equipment industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 10% per year. Haemonetics's return on equity is 20.4%, and it has net margins of 12.3%.
Key information
15.22%
Earnings growth rate
15.24%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | 10.00% |
| Return on equity | 20.43% |
| Net Margin | 12.32% |
| Last Earnings Update | 29 Mar 2025 |
Recent past performance updates
Recent updates
Do Haemonetics' (NYSE:HAE) Earnings Warrant Your Attention?
May 10
Is Haemonetics (NYSE:HAE) Using Too Much Debt?
Mar 18Haemonetics: Almost Blood In The Streets
Feb 20Haemonetics (NYSE:HAE) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 13Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings
Dec 06These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09
Innovative Express Plus Technology And Strategic Market Expansion Set To Propel Revenue Growth
Sep 03 Innovation and R&D in Blood Management Technologies, including new products, are expected to increase market share and net margins through product differentiation.What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Revenue & Expenses Breakdown
How Haemonetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Mar 25 | 1,361 | 168 | 437 | 63 |
| 28 Dec 24 | 1,374 | 130 | 420 | 61 |
| 28 Sep 24 | 1,361 | 124 | 421 | 58 |
| 29 Jun 24 | 1,334 | 115 | 419 | 54 |
| 30 Mar 24 | 1,309 | 118 | 421 | 52 |
| 30 Dec 23 | 1,270 | 127 | 401 | 53 |
| 30 Sep 23 | 1,239 | 128 | 390 | 53 |
| 01 Jul 23 | 1,219 | 137 | 376 | 51 |
| 01 Apr 23 | 1,169 | 115 | 374 | 49 |
| 31 Dec 22 | 1,129 | 96 | 375 | 47 |
| 01 Oct 22 | 1,084 | 86 | 360 | 44 |
| 02 Jul 22 | 1,026 | 68 | 334 | 44 |
| 02 Apr 22 | 993 | 43 | 332 | 46 |
| 01 Jan 22 | 953 | 23 | 296 | 43 |
| 02 Oct 21 | 934 | 31 | 282 | 41 |
| 03 Jul 21 | 903 | 64 | 279 | 37 |
| 03 Apr 21 | 870 | 79 | 264 | 32 |
| 26 Dec 20 | 884 | 108 | 229 | 31 |
| 26 Sep 20 | 903 | 106 | 241 | 30 |
| 27 Jun 20 | 946 | 96 | 256 | 30 |
| 28 Mar 20 | 988 | 77 | 266 | 30 |
| 28 Dec 19 | 999 | 80 | 293 | 29 |
| 28 Sep 19 | 988 | 68 | 296 | 31 |
| 29 Jun 19 | 977 | 49 | 294 | 33 |
| 30 Mar 19 | 968 | 55 | 262 | 35 |
| 29 Dec 18 | 952 | 46 | 300 | 38 |
| 29 Sep 18 | 939 | 21 | 317 | 41 |
| 30 Jun 18 | 922 | 23 | 316 | 40 |
| 31 Mar 18 | 904 | 46 | 278 | 35 |
| 30 Dec 17 | 898 | -17 | 309 | 37 |
| 30 Sep 17 | 892 | 4 | 283 | 33 |
| 01 Jul 17 | 887 | 4 | 280 | 34 |
| 01 Apr 17 | 886 | -26 | 302 | 38 |
| 31 Dec 16 | 900 | 16 | 306 | 39 |
| 01 Oct 16 | 906 | -59 | 314 | 42 |
| 02 Jul 16 | 905 | -66 | 317 | 45 |
| 02 Apr 16 | 909 | -56 | 317 | 45 |
| 26 Dec 15 | 893 | -50 | 319 | 51 |
| 26 Sep 15 | 891 | 26 | 322 | 51 |
| 27 Jun 15 | 899 | 20 | 332 | 50 |
| 28 Mar 15 | 910 | 17 | 337 | 54 |
| 27 Dec 14 | 925 | 30 | 348 | 51 |
| 27 Sep 14 | 935 | 30 | 396 | 54 |
| 28 Jun 14 | 943 | 39 | 382 | 58 |
Quality Earnings: HAE has high quality earnings.
Growing Profit Margin: HAE's current net profit margins (12.3%) are higher than last year (9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HAE's earnings have grown by 15.2% per year over the past 5 years.
Accelerating Growth: HAE's earnings growth over the past year (42.5%) exceeds its 5-year average (15.2% per year).
Earnings vs Industry: HAE earnings growth over the past year (42.5%) exceeded the Medical Equipment industry 15.1%.
Return on Equity
High ROE: Whilst HAE's Return on Equity (20.43%) is high, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 23:53 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/29 |
| Annual Earnings | 2025/03/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Haemonetics Corporation is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Ishan Majumdar | Baptista Research |
| Gary Prestopino | Barrington Research Associates, Inc. |